Celtaxsys to Present at Jefferies Healthcare and JMP Securities Life Sciences Conferences
May 23, 2016 08:02 ET
|
Celtaxsys Inc.
ATLANTA, GA--(Marketwired - May 23, 2016) - Celtaxsys, Inc., a clinical stage pharmaceutical company focused on developing anti-inflammatory therapies for cystic fibrosis (CF) lung disease and...
Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis
May 03, 2016 08:03 ET
|
Celtaxsys, Inc.
ATLANTA, GA--(Marketwired - May 03, 2016) - Celtaxsys, a clinical stage drug development company focused on advancing therapies for patients with rare and orphan inflammatory diseases, announced...
Celtaxsys to Present at 27th Annual Piper Jaffray Healthcare Conference
December 01, 2015 08:03 ET
|
Celtaxsys Inc.
ATLANTA, GA--(Marketwired - December 01, 2015) - Celtaxsys, a clinical stage drug development company focused on advancing foundational medicine for patients suffering from orphan inflammatory...
Celtaxsys to Present Clinical Data on Oral Acebilustat at North American Cystic Fibrosis Conference: Key Inflammation Biomarkers Reduced in CF Patients
October 01, 2015 08:03 ET
|
Celtaxsys Inc.
ATLANTA, GA--(Marketwired - October 01, 2015) - Celtaxsys, a clinical stage drug development company focused on advancing care for patients suffering from orphan inflammatory diseases, announced today...